Show simple item record

dc.contributor.authorAronowitz, Jesse N.
dc.contributor.authorDing, Linda
dc.contributor.authorYates, Jennifer K.
dc.contributor.authorZong, Yang
dc.contributor.authorZheng, Larry Z.
dc.contributor.authorJiang, Zhong
dc.contributor.authorYancey, Jessica
dc.contributor.authorMittal, Kriti
dc.contributor.authorFitzgerald, Thomas J.
dc.date2022-08-11T08:10:49.000
dc.date.accessioned2022-08-23T17:21:22Z
dc.date.available2022-08-23T17:21:22Z
dc.date.issued2021-03-12
dc.date.submitted2021-04-12
dc.identifier.citation<p>Aronowitz J, Ding L, Yates J, Zong Y, Zheng L, Jiang Z, Yancey J, Mittal K, Fitzgerald TJ. Stereotactic Body Radiotherapy for Palliation of Hematuria Arising From Urothelial Carcinoma of the Kidney in Unfavorable Surgical Candidates. Am J Clin Oncol. 2021 Mar 12. doi: 10.1097/COC.0000000000000801. Epub ahead of print. PMID: 33710134. <a href="https://doi.org/10.1097/COC.0000000000000801">Link to article on publisher's site</a></p>
dc.identifier.issn0277-3732 (Linking)
dc.identifier.doi10.1097/COC.0000000000000801
dc.identifier.pmid33710134
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48503
dc.description.abstractINTRODUCTION: Hematuria can be a distressing and debilitating complication of urothelial carcinoma (UC) of the kidney for patients who are not candidates for surgery or ureteroscopic ablation. We retrospectively assessed the efficacy, tolerability, and safety of stereotactic body radiotherapy (SBRT) for controlling gross hematuria in this patient population. MATERIALS AND METHODS: Institutional Review Board (IRB)-approved review of the records, laboratory values, pathology, and imaging of 8 consecutive patients treated with SBRT over a 5-year period for uncontrolled gross hematuria caused by UC of the renal pelvis or calyces. RESULTS: Therapy was delivered in 3 to 5 treatments over 1 to weeks. Individual treatments lasted an average of 17.2 minutes. No patient experienced treatment-related pain, vomiting, or diarrhea. All enjoyed cessation of bleeding within a week of completing therapy. Hematuria recurred in 2 patients in 4 and 22 months. Of the patients who have not re-bled, 3 expired of metastatic disease or co-morbidities, and 3 remain alive up to 6 years posttreatment. Of patients who have survived longer than a year, creatinine has changed by -0.05 to +0.35, and estimated glomerular filtration rate has fallen by an average of 22%. No patient has required dialysis. CONCLUSIONS: SBRT appears to be an effective and well-tolerated means of palliating gross hematuria secondary to UC of the renal pelvis or calyces in patients who are unfavorable candidates for nephrectomy or ureteroscopic ablation. Treatment was associated with a moderate decline in renal function.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33710134&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1097/coc.0000000000000801
dc.subjectFemale Urogenital Diseases and Pregnancy Complications
dc.subjectMale Urogenital Diseases
dc.subjectNeoplasms
dc.subjectOncology
dc.subjectPathological Conditions, Signs and Symptoms
dc.subjectRadiation Medicine
dc.subjectRadiology
dc.titleStereotactic Body Radiotherapy for Palliation of Hematuria Arising From Urothelial Carcinoma of the Kidney in Unfavorable Surgical Candidates
dc.typeArticle
dc.source.journaltitleAmerican journal of clinical oncology
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiology_pubs/604
dc.identifier.contextkey22442992
html.description.abstract<p>INTRODUCTION: Hematuria can be a distressing and debilitating complication of urothelial carcinoma (UC) of the kidney for patients who are not candidates for surgery or ureteroscopic ablation. We retrospectively assessed the efficacy, tolerability, and safety of stereotactic body radiotherapy (SBRT) for controlling gross hematuria in this patient population.</p> <p>MATERIALS AND METHODS: Institutional Review Board (IRB)-approved review of the records, laboratory values, pathology, and imaging of 8 consecutive patients treated with SBRT over a 5-year period for uncontrolled gross hematuria caused by UC of the renal pelvis or calyces.</p> <p>RESULTS: Therapy was delivered in 3 to 5 treatments over 1 to weeks. Individual treatments lasted an average of 17.2 minutes. No patient experienced treatment-related pain, vomiting, or diarrhea. All enjoyed cessation of bleeding within a week of completing therapy. Hematuria recurred in 2 patients in 4 and 22 months. Of the patients who have not re-bled, 3 expired of metastatic disease or co-morbidities, and 3 remain alive up to 6 years posttreatment. Of patients who have survived longer than a year, creatinine has changed by -0.05 to +0.35, and estimated glomerular filtration rate has fallen by an average of 22%. No patient has required dialysis.</p> <p>CONCLUSIONS: SBRT appears to be an effective and well-tolerated means of palliating gross hematuria secondary to UC of the renal pelvis or calyces in patients who are unfavorable candidates for nephrectomy or ureteroscopic ablation. Treatment was associated with a moderate decline in renal function.</p>
dc.identifier.submissionpathradiology_pubs/604
dc.contributor.departmentDepartment of Medicine, Division of Hematology Oncology
dc.contributor.departmentDepartment of Radiology
dc.contributor.departmentDepartment of Pathology
dc.contributor.departmentDepartment of Urology
dc.contributor.departmentDepartment of Radiation Oncology


This item appears in the following Collection(s)

Show simple item record